Kostas Biliouris
Stock Analyst at BMO Capital
(1.91)
# 1,446
Out of 4,479 analysts
41
Total ratings
34.29%
Success rate
-6.32%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $234 | $247.61 | -5.50% | 4 | Jun 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $154.20 | +29.70% | 4 | Jun 24, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $120 | $33.11 | +262.43% | 3 | May 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $62 → $70 | $22.15 | +216.03% | 5 | May 10, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $15 | $8.77 | +71.04% | 4 | Apr 1, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $70 → $63 | $20.58 | +206.12% | 3 | Apr 1, 2024 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 | $22.57 | +152.55% | 3 | Mar 27, 2024 | |
| MGX Metagenomi | Initiates: Outperform | $22 | $4.23 | +420.09% | 1 | Mar 5, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Market Perform | $37 | $24.91 | +48.53% | 1 | Jan 31, 2024 | |
| SLN Silence Therapeutics | Initiates: Outperform | $67 | $18.06 | +270.99% | 1 | Jan 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $102 → $100 | $82.22 | +21.62% | 4 | Nov 3, 2023 | |
| PRME Prime Medicine | Initiates: Outperform | $19 | $5.28 | +259.85% | 1 | Oct 9, 2023 | |
| LEGN Legend Biotech | Maintains: Outperform | $79 → $90 | $44.74 | +101.16% | 2 | Apr 25, 2023 | |
| DTIL Precision BioSciences | Downgrades: Market Perform | $210 → $120 | $9.41 | +1,175.24% | 2 | Mar 14, 2023 | |
| VERV Verve Therapeutics | Maintains: Outperform | $48 → $62 | $5.00 | +1,140.00% | 2 | Jul 18, 2022 | |
| CRSP CRISPR Therapeutics AG | Initiates: Outperform | $98 | $53.12 | +84.51% | 1 | Jun 17, 2022 |
Alnylam Pharmaceuticals
Jun 24, 2024
Maintains: Outperform
Price Target: $234
Current: $247.61
Upside: -5.50%
Sarepta Therapeutics
Jun 24, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $154.20
Upside: +29.70%
Korro Bio
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $33.11
Upside: +262.43%
Intellia Therapeutics
May 10, 2024
Maintains: Outperform
Price Target: $62 → $70
Current: $22.15
Upside: +216.03%
Centessa Pharmaceuticals
Apr 1, 2024
Maintains: Outperform
Price Target: $15
Current: $8.77
Upside: +71.04%
4D Molecular Therapeutics
Apr 1, 2024
Maintains: Outperform
Price Target: $70 → $63
Current: $20.58
Upside: +206.12%
Beam Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $22.57
Upside: +152.55%
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: $22
Current: $4.23
Upside: +420.09%
BridgeBio Pharma
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $24.91
Upside: +48.53%
Silence Therapeutics
Jan 31, 2024
Initiates: Outperform
Price Target: $67
Current: $18.06
Upside: +270.99%
BioMarin Pharmaceutical
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $82.22
Upside: +21.62%
Prime Medicine
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $5.28
Upside: +259.85%
Legend Biotech
Apr 25, 2023
Maintains: Outperform
Price Target: $79 → $90
Current: $44.74
Upside: +101.16%
Precision BioSciences
Mar 14, 2023
Downgrades: Market Perform
Price Target: $210 → $120
Current: $9.41
Upside: +1,175.24%
Verve Therapeutics
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $5.00
Upside: +1,140.00%
CRISPR Therapeutics AG
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $53.12
Upside: +84.51%